<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Chemical terrorism: Rapid recognition and initial medical management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Chemical terrorism: Rapid recognition and initial medical management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Chemical terrorism: Rapid recognition and initial medical management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James M Madsen, MD, MPH, COL (ret), MC-FS, USA
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michele M Burns, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrew Stolbach, MD, MPH, FAACT, FACMT, FACEP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Ganetsky, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 24, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Potential actions by terrorist groups span the chemical, biological, radiological, nuclear, and high explosive (CBRNE) threat spectrum [
         <a href="#rid1">
          1
         </a>
         ]. This topic provides guidance for the rapid recognition and initial management of patients exposed to the chemical agents that are most likely to be used in warfare or by terrorists.
        </p>
        <p>
         Bioterrorism and clinical features and treatment of radiation exposure, including exposure cause by acts of nuclear terrorism, are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/2735.html" rel="external">
          "Identifying and managing casualties of biological terrorism"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6589.html" rel="external">
          "Clinical manifestations, evaluation, and diagnosis of acute radiation exposure"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6588.html" rel="external">
          "Management of radiation injury"
         </a>
         .)
        </p>
        <p>
         Planning and preparation for field and medical response to weapons of mass destruction are beyond the scope of this topic but are reviewed elsewhere [
         <a href="#rid2">
          2-11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          BACKGROUND
         </span>
         <span class="headingEndMark">
          —
         </span>
         The use of chemical weapons violates current international law and is governed by treaties administered by the United Nations (UN). Since 1997, the Convention on the Prohibition of the Development, Production, Stockpiling and Use of Chemical Weapons and on Their Destruction, or Chemical Weapons Convention (CWC), has been in force. The CWC is administered by the Organisation for the Prohibition of Chemical Weapons (OPCW), in The Hague, Netherlands [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
         Despite international prohibitions against the use of chemical weapons, large amounts of various agents remain available in national stockpiles in several countries, and their use against military and civilian populations has been reported as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of nerve and sulfur mustard [H] agents by Iraq against military targets in Iran and Kurdish villages (eg, Halabjah) in northern Iraq [
         <a href="#rid13">
          13,14
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Terrorist use of sarin (GB) and VX by members of the Japanese cult Aum Shinrikyo [
         <a href="#rid15">
          15,16
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assassinations using the nerve agent VX by the group Aum Shinrikyo [
         <a href="#rid17">
          17
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improvised explosive devices rigged to release chlorine gas by Iraqi insurgents [
         <a href="#rid18">
          18
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of chlorine in barrel bombs in Syria and Iraq [
         <a href="#rid19">
          19,20
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of sarin in Ghouta and Khan Shaykun, Syria [
         <a href="#rid21">
          21-25
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assassination attempts using Novichok [
         <a href="#rid26">
          26,27
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Risk of chemical agent use in Ukraine [
         <a href="#rid28">
          28
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         In addition, many chemicals that are commonly used for industrial or commercial purposes are not prohibited by the CWC and have the potential for causing mass casualties.
        </p>
        <p class="headingAnchor" id="H1326909">
         <span class="h1">
          CHEMICAL AGENT DEFINITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chemical agents capable of causing mass casualties are described by several categories as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Traditional chemical weapons
         </strong>
         – Traditional chemical weapons refer to known agents that have been stockpiled by nations for use during war and will be the focus of this topic.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The North Atlantic Treaty Organization (NATO) has assigned a one- to three-character designation (often called a NATO code) to each of the traditional agents; for agents such as VX (O-ethyl S-[2-(diisopropylamino) ethyl] methylphosphonothioate) and BZ (3-quinuclidinyl benzilate), this code may be more widely used than the chemical name of the compound.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Categories of chemical weapons include [
         <a href="#rid29">
          29,30
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pulmonary agents (eg, chlorine or phosgene [GG])
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         "Blood" agents (eg, cyanide compounds [AC])
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Vesicants (blister agents such as sulfur mustard [H] compounds)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nerve agents (eg, tabun [GA], sarin [GB], soman [GD], VX, and Novichok, including A-series agents [
         <a href="#rid31">
          31
         </a>
         ]):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In contrast with so-called first-generation chemical agents (used during World War I), nerve agents include:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Second-generation agents (the G-series agents developed by Germany before and during World War II) – These are nonpersistent liquids that evaporate relatively quickly.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Third-generation agents (V-series agents, developed by the United Kingdom and the United States shortly after the end of World War II) – These are persistent liquids and are more potent than the G agents.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Fourth-generation agents (FGAs), developed by the former Soviet Union beginning in the 1970s as "Novichok" agents and including A-series agents – These are even more persistent than V-series agents.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         The onset of the clinical effects of nerve agents depends on the dose, the state or states (mainly vapor versus liquid), and route(s) of exposure (mainly inhalation versus dermal exposure). Skin exposure to liquid Novichok agents is a special case because of the extremely long latent periods (up to two days), the difficulty of treating symptomatic patients [
         <a href="#rid27">
          27
         </a>
         ], and the importance of actions taken during the latent period.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Incapacitating agents (eg, the anticholinergic agent, BZ [3-quinuclidinyl benzilate, or QNB])
        </p>
        <p>
        </p>
        <p>
         Some compounds, such as chlorine, phosgene, and cyanide, have been used in war and are also used in industry; these are sometimes termed
         <strong>
          dual-use
         </strong>
         chemicals.
        </p>
        <p>
         Although arsenicals (eg, arsine, ethyldichloroarsine [ED], methyldichloroarsine [MD] and phenyldichloroarsine [PD]) have characteristics that would make them attractive as a chemical weapon, they are primarily of historic interest and have not been stockpiled to any great degree [
         <a href="#rid32">
          32
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Crowd-control agents
         </strong>
         – The Chemical Weapons Convention (CWC) also regards crowd-control agents, for example OC (ie, oleoresin capsicum) and CS (o-chlorobenzylidene malononitrile), as weaponized chemical agents. The lay term "tear gas" is sometimes used to refer to some or all of these agents but is not an official military term and, in addition, is a misnomer since these agents are all solids at ambient temperatures and are dispersed as aerosols (eg, smokes or sprays) rather than as gases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Binary chemical weapons
         </strong>
         – Binary chemical weapons are not separate compounds; instead the term refers to the practice of developing munitions that hold two immediate precursors to a chemical agent in separate compartments divided by a membrane that ruptures when the round is launched. The precursors mix in flight and generate the desired chemical agent.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The CWC prohibits several important precursors to chemical agents, but given their availability, synthesis of even complex nerve agents is not beyond the reach of those with graduate-level training in chemistry, as the Aum Shinrikyo cult demonstrated with their nerve agent attacks in the Tokyo subway [
         <a href="#rid15">
          15,16
         </a>
         ]. The simpler chemical agents can be synthesized even more easily or, in the case of dual-use agents, simply purchased or stolen.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Toxic industrial chemicals
         </strong>
         – Toxic industrial chemicals, or TICs, include a variety of industrial chemicals that have the potential for causing mass casualties including hydrogen fluoride, ammonia, formaldehyde, hydrogen sulfide, phosphine, and sulfuric acid [
         <a href="#rid29">
          29,33,34
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, serious chemical exposure does not require an industrial source. For example, "detergent suicides," the intentional mixing of common household products to produce toxic compounds such as hydrogen cyanide and hydrogen sulfide, demonstrate how easily toxic chemicals can be made using commercially available substances [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In the United States, local resources to identify TICs or dangerous commercial chemicals primarily reside in fire departments. Decontamination procedures and medical management of TIC or dangerous commercial chemical exposure vary according to agent. Resources to assist the clinician are available online. (See
         <a class="local">
          'Additional resources'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nontraditional agents
         </strong>
         – This term refers to newer chemical agents that have been synthesized and weaponized outside the United States [
         <a href="#rid29">
          29
         </a>
         ]. This category is redefined over time; certain A-series nerve agents, for example, used to be in this category but are now considered traditional agents.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mid-spectrum agents
         </strong>
         – Mid-spectrum agents are chemical poisons produced by biological organisms (eg, ricin, T-2 mycotoxins, and botulinum toxin) and are also considered chemical agents by the CWC [
         <a href="#rid36">
          36,37
         </a>
         ]. These agents are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2735.html" rel="external">
          "Identifying and managing casualties of biological terrorism", section on 'Toxins of concern'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H343090">
         <span class="h1">
          RECOGNITION OF CHEMICAL EXPOSURE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The algorithm provides a means of rapid recognition of chemical exposure based upon clinical findings (
         <a class="graphic graphic_algorithm graphicRef90159" href="/z/d/graphic/90159.html" rel="external">
          algorithm 1
         </a>
         ). The table provides suggested decontamination and management according to chemical agent (
         <a class="graphic graphic_table graphicRef90716" href="/z/d/graphic/90716.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Recognition of chemical exposure can come from features of the exposure, clinical syndromes, and laboratory testing. Of these, laboratory testing of body fluids or tissues takes too long to play more than a confirmatory role in a mass-casualty incident or to document noncompliance with the United Nations Chemical Weapons Convention Treaty [
         <a href="#rid38">
          38
         </a>
         ]. However, preservation of decontamination fluids and samples of blood, urine, hair, and any foreign material taken from patients is an important forensic consideration during care.
        </p>
        <p>
         Less commonly, announcements by perpetrators may identify the chemical agent, although confirmation of the agent is often necessary to ensure that a chemical exposure has indeed occurred and to verify that the terrorist claims are true.
        </p>
        <p class="headingAnchor" id="H343612">
         <span class="h2">
          Features of chemical exposures
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many of the features of chemical exposures potentially overlap with those of exposures to toxins or weaponized biological agents. Presenting features suggesting a chemical exposure include the following (
         <a class="graphic graphic_table graphicRef90149" href="/z/d/graphic/90149.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid39">
          39-41
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Timing
         </strong>
         – The sudden onset of symptoms within minutes among multiple exposed patients should suggest the use of chemical agents, especially nerve agents or cyanide [
         <a href="#rid40">
          40
         </a>
         ]. By contrast, biologic agents may take many hours to weeks to become apparent. (See
         <a class="medical medical_review" href="/z/d/html/2735.html" rel="external">
          "Identifying and managing casualties of biological terrorism"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, the latent period (the length of time between exposure and the appearance of signs or symptoms in casualties) may be more on the order of hours for type II pulmonary, sulfur mustard, or BZ agents. As a general rule, the higher the dose of a chemical agent, the shorter the latent period. Also, skin exposures to liquid nerve agents may require several minutes to several hours for the agent to undergo absorption and produce clinically observable effects.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unusual fogs or smokes
         </strong>
         – Most chemicals of interest (eg, VX, mustard vapor, phosgene, or chlorine) are heavier than air and stay low to the ground. They may be deployed by an explosive device that causes little or no structural damage. In some instances, the physical characteristics such as odor, taste, or color of the released chemical can help identify it as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Chlorine
         </strong>
         – Yellow-green gas with a characteristic chlorine odor [
         <a href="#rid42">
          42
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Phosgene
         </strong>
         – Colorless gas or white cloud with odor of newly mown or musty hay, grass, or corn [
         <a href="#rid42">
          42
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cyanide
         </strong>
         – Odor of bitter almonds (less commonly, of burning rope or of acetylene) (only about 50 percent of people can detect this smell) [
         <a href="#rid42">
          42
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Sulfur mustard
         </strong>
         – Yellow-brown vapor, yellow liquid, or solid that is odorless or smells like onions, garlic, mustard, or asphalt [
         <a href="#rid43">
          43
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tabun (nerve agent)
         </strong>
         – Colorless and tasteless with a slight fruity odor [
         <a href="#rid44">
          44
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Sarin (nerve agent)
         </strong>
         – Colorless and tasteless, often with a faint fruity odor [
         <a href="#rid44">
          44
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Soman (nerve agent)
         </strong>
         – Colorless and tasteless with an odor described as sweet, musty, fruity, nutty, or like
         <a class="drug drug_general" data-topicid="104178" href="/z/d/drug information/104178.html" rel="external">
          camphor
         </a>
         [
         <a href="#rid44">
          44
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          VX (nerve agent)
         </strong>
         – Amber color, possibly faintly fishy odor, and tasteless [
         <a href="#rid44">
          44
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          BZ
         </strong>
         – Colorless, odorless, and tasteless
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Crowd-control agents
         </strong>
         – Colorless, odorless, and tasteless in solid form; extremely irritating (bypassing most descriptions of odor) when inhaled in aerosolized form
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Common clinical findings among multiple patients within a short period of time (minutes to hours)
         </strong>
         . (See
         <a class="local">
          'Clinical syndromes'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients were located near or downwind from the release
         </strong>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sentinel case (illness due to an uncommon agent)
         </strong>
         – For example, initial casualties with high exposure followed by those exposed to lesser doses or a liquid form of the chemical weapon.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Failure to respond to usual therapy
         </strong>
         – As an example, patients with exposure to pulmonary agents may have unremitting respiratory failure despite advanced therapies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unexplained human deaths
         </strong>
         – Mass casualties without evidence of trauma suggests a chemical or biological exposure.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Unexplained deaths of animals, fish, or plants
         </strong>
         – A biological or liquid chemical release may be persistent, although a gas release tends to disperse [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H343619">
         <span class="h2">
          Clinical syndromes
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical diagnosis of exposure to chemical agents is aided by familiarity with presenting clinical signs and symptoms of chemical weapons exposure and the signs and symptoms that suggest exposure to cholinergic and anticholinergic agents. An algorithm can assist in rapid diagnosis of a chemical weapons exposure (
         <a class="graphic graphic_algorithm graphicRef90159" href="/z/d/graphic/90159.html" rel="external">
          algorithm 1
         </a>
         ). The table provides suggested decontamination and management according to chemical agent (
         <a class="graphic graphic_table graphicRef90716" href="/z/d/graphic/90716.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         First responders and clinicians must take precautions to protect themselves prior to approaching suspected victims of a chemical weapons exposure and rendering care. (See
         <a class="local">
          'Protection of providers'
         </a>
         below and
         <a class="local">
          'Stabilization'
         </a>
         below and
         <a class="local">
          'Initial management of specific exposures'
         </a>
         below.)
        </p>
        <p>
         The main toxidromes, or constellations of signs and symptoms that suggest terrorist release of chemical weapons and potential compounds, include the following (
         <a class="graphic graphic_algorithm graphicRef90159" href="/z/d/graphic/90159.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid3">
          3,40,41,44
         </a>
         ]:
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Coma or seizures – Cyanide, hydrogen sulfide, opioids, or, if cholinergic findings are present (eg, miosis, bronchorrhea, wheezing, tearing, vomiting, diarrhea, sweating, fasciculations, or paralysis), nerve agents
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Rapid onset of respiratory distress with eye, nose, or throat irritation – Chlorine or other combination pulmonary agents, type I pulmonary agents (eg, ammonia, other bases, or acids), crowd-control agents, or Lewisite
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cholinergic findings (eg, miosis, bronchorrhea, wheezing, tearing, vomiting, diarrhea, sweating, fasciculations, or paralysis) – Nerve agents
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Delayed onset of chest tightness and pulmonary edema – Phosgene or other type II pulmonary agents
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Skin erythema, burns, or conjunctivitis – Sulfur mustard agents, phosgene (contact with liquid form), crowd-control agents, hydrogen fluoride, Lewisite
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Disorientation with anticholinergic findings (flushed dry skin, dilated pupils, tachycardia, or hypertension) – BZ
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Rotten-egg odor followed by olfactory paralysis; "knockdown" (sudden collapse); conjunctivitis ("gas eye"); and pulmonary edema – Hydrogen sulfide [
         <a href="#rid45">
          45
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         By contrast, clinical features consisting of fever, rash, or gastrointestinal bleeding suggest exposure to a biologic agent or toxin (
         <a class="graphic graphic_table graphicRef90149" href="/z/d/graphic/90149.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2735.html" rel="external">
          "Identifying and managing casualties of biological terrorism"
         </a>
         .)
        </p>
        <p>
         Key questions to answer during a thorough secondary survey in mass-casualty incidents involving chemical agents can be recalled using the mnemonic ASBESTOS as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          A
         </strong>
         : Agent – Is a clinical toxic syndrome (toxidrome) present? What are the results of rapid detection or other features of the release that can identify the exposure? (See
         <a class="local">
          'Rapid detection and ancillary studies'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          S
         </strong>
         : State – Is the chemical exposure caused by a vapor, liquid, aerosol, gas, or combination?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          B
         </strong>
         : Body site of exposure – Was the chemical inhaled, ingested, or dermally absorbed?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          E
         </strong>
         : Effects – What kind of effects are present; local (at or near the body site of exposure), systemic, or both?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          S
         </strong>
         : Severity – How severe is the exposure? What is the severity of the clinical effects?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          T
         </strong>
         : Time course – How long has it been between exposure and onset of symptoms? Is the patient getting worse or better over time?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          O
         </strong>
         : Other diagnoses – What comorbidities does the patient have (eg, asthma)? What is the differential diagnosis for the clinical findings?
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          S
         </strong>
         : Synergism – Are there combined effects caused by multiple exposures?
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H343743">
         <span class="h2">
          Rapid detection and ancillary studies
         </span>
        </p>
        <p class="headingAnchor" id="H3984338008">
         <span class="h3">
          Rapid detection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clues to the identity of a released chemical agent may come from any of the following [
         <a href="#rid46">
          46
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Announcement by the perpetrators
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intelligence sources
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Environmental detectors
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Large-area vapor monitors (eg, M21, Joint Services Lightweight Standoff Chemical Agent Detector)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Personal-space vapor monitors (M256A2, ICAD)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Liquid detectors (M8 paper, M9 paper)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Biological sampling of fluid or tissues from those suspected of having been exposed [
         <a href="#rid47">
          47
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serum electrolytes, lactate, anion gap, CBC with differential
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Special tests for specific compounds (usually not fast enough for use in initial treatment; may be useful in later confirmation)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical suspicion and identification of toxidromes
        </p>
        <p>
        </p>
        <p>
         There are problems inherent in each of these sources; eg, announcements may be deliberately misleading, intelligence may be faulty, false positives and false negatives may be significant with environmental detectors, a given detector may not detect the agent in the state in which it is present, results from laboratory tests may not be definitive or may take too long, and clinical findings may vary for patients with the same exposure.
        </p>
        <p>
         In many situations, the most reliable initial detector may be clinical recognition of toxidromes. (See
         <a class="local">
          'Clinical syndromes'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3463678353">
         <span class="h3">
          Ancillary studies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with significant respiratory distress, regardless of the cause, warrant the following studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Blood gas measurement
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count (CBC)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chest radiograph
        </p>
        <p>
        </p>
        <p>
         Additional studies obtained in the course of patient care help to confirm the clinical impression and, in some instances, document exposure by a specific agent as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cyanide
         </strong>
         (see
         <a class="medical medical_review" href="/z/d/html/299.html" rel="external">
          "Cyanide poisoning", section on 'Laboratory evaluation'
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serum lactate – Elevated
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serum electrolytes – Elevated anion gap
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Arterial and central venous blood gas – Metabolic acidosis, decreased arteriovenous oxygen gradient (usually from a higher-than-usual venous oxygen content)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Blood or urine cyanide level – Confirms exposure (rarely if ever available in time to contribute to real-time patient care)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nerve agent
         </strong>
         (see
         <a class="medical medical_review" href="/z/d/html/339.html" rel="external">
          "Organophosphate and carbamate poisoning", section on 'Laboratory abnormalities'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Decreased red blood cell acetylcholinesterase – Confirms nerve agent exposure and can help guide oxime therapy
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Decreased pseudocholinesterase – Assists in documenting nerve agent exposure
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sulfur mustard
         </strong>
         [
         <a href="#rid43">
          43
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Serial daily CBCs – Leukopenia (typically begins day three to five days after exposure) after an initial leukocytosis
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Urinary thiodiglycol (investigational) – Elevated
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         DNA and protein adducts (investigational) – Elevated
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lewisite
         </strong>
         [
         <a href="#rid43">
          43
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         CBC – Hemolytic anemia (large dose exposure)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Urinary arsenic – Elevated
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Urinary 2-chlorovinylarsonous acid (CVAA) (investigational) – Elevated [
         <a href="#rid48">
          48
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2753652">
         <span class="h1">
          FIELD INCIDENT RESPONSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The medical field actions necessary to respond to a chemical terrorism incident are provided in detail by the United States Department of Health and Human Services
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fchemm.hhs.gov%2Fonsite.htm&amp;token=dp%2BhZUZL0R27seNHDAv8lCcJIoihPRtVOIJexrT11Xg%2BKrbG6g2m1%2Fd08h8tXF3i&amp;TOPIC_ID=2020" target="_blank">
          here
         </a>
         . In many civilian jurisdictions, the fire department is in charge of the incident.
        </p>
        <p>
         Key activities include [
         <a href="#rid49">
          49
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Notify local authorities
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Establish local on-site incident command
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Establish the following control zones and perimeter security
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Hot zone
         </strong>
         – Contaminated area or site of release, entry granted only to properly attired rescuers (first responders)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Warm zone
         </strong>
         – Located uphill and upwind of hot zone, this area is designated for decontamination of victims and rescuers (first responders). Personnel performing decontamination and early medical care (first receivers) must be properly attired
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cold (support) zone
         </strong>
         – Clean area where victims who are free of external liquid contamination are received and transported to definitive care
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Ensure protection of first responders and receivers
         </strong>
         – Guidelines for personal protective equipment (PPE) to be worn by first responders and first receivers are provided by the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.osha.gov%2Femergency-preparedness%2Fhazardous-waste-operations%2Ffaq-hazpower%23faq7&amp;token=h5gB8MJg7Rf4cMTS1zSLvwytWqjIcNhP7MXHubnbs8ZjMZXIORr08tqRjlnAJpHt78KXJG%2BNrL9juS3aluAhTxab%2FJK7%2BWs1aalo5WwT8iNkWQ2FzXhRsK0v1EUTvgaD&amp;TOPIC_ID=2020" target="_blank">
          United States Occupational Safety and Health Administration
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Personal protection for first receivers are discussed separately. (See
         <a class="local">
          'Protection of providers'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For a suspected chemical terrorism incident, first responders who are evacuating victims from the hot zone should wear level A personal protective equipment (PPE) consisting of the following [
         <a href="#rid50">
          50
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Positive pressure, full face-piece, self-contained breathing apparatus (SCBA)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Fully encapsulating chemical protective suit with suit openings sealed with tape
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Two pairs of chemical resistant gloves
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chemical resistant boots with a steel toe and shank
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hard hat, as needed, based upon conditions
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Disposable protective suit, gloves and boots (may be worn over fully encapsulating suit)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Identify chemical hazard
         </strong>
         (
         <a class="graphic graphic_algorithm graphicRef90159" href="/z/d/graphic/90159.html" rel="external">
          algorithm 1
         </a>
         ) (see
         <a class="local">
          'Clinical syndromes'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Determine extent of threat and affected population
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Begin patient triage
         </strong>
         – Field triage guidance for chemical casualties and the triage algorithms, Simple Triage and Rapid Treatment (START and JumpSTART) and Sort – Assess – Life Saving Interventions (SALT) are discussed in detail
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fchemm.hhs.gov%2Ftriage.htm&amp;token=dp%2BhZUZL0R27seNHDAv8lGD46Sguvkt8B1wx5f39OfSWOPJDxA9TaLgkJwbjICFr&amp;TOPIC_ID=2020" target="_blank">
          here
         </a>
         . Additional considerations specific to triage of victims of chemical exposures are discussed below. (See
         <a class="local">
          'Triage'
         </a>
         below and
         <a class="local">
          'Special considerations for chemical events'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2063369">
         <span class="h1">
          HOSPITAL INCIDENT RESPONSE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Upon notification of a chemical weapons release, receiving facilities should secure all entrances and hospital grounds, establish a security perimeter, and set up a decontamination zone that is outside the clean parts of the facility. Disaster plans should be activated. Facility incident command and close communication with local emergency management authorities should be established.
        </p>
        <p>
         Planning and preparation for field and medical response to weapons of mass destruction are beyond the scope of this topic and are provided elsewhere [
         <a href="#rid2">
          2-11
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4870432">
         <span class="h1">
          INITIAL MANAGEMENT OF CHEMICAL EXPOSURES
         </span>
        </p>
        <p class="headingAnchor" id="H12470257">
         <span class="h2">
          Protection of providers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Providers responding to release of an unknown chemical should wear personal protective equipment (PPE) designed to protect against the highest possible personal threat. The levels of PPE as designated by the Occupational Safety and Health Administration are available
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.osha.gov%2Flaws-regs%2Fregulations%2Fstandardnumber%2F1910%2F1910.120AppB&amp;token=cBdz3Q1CH7IVGsHQmyQigtfn%2BaDVRU0eDZjMBw5O6b7cs7yLDsrQCaoVNpj%2BFigGHpksD08Fp6NLAj2J2Z9%2BnSFc1D7lxZk8Knu31Gn6Vc0%3D&amp;TOPIC_ID=2020" target="_blank">
          here
         </a>
         .
        </p>
        <p>
         Appropriate personal protective equipment for a chemical terrorism event by provider type and location of care include the following [
         <a href="#rid51">
          51-53
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          First responders
         </strong>
         – First responders who enter the site of an unknown chemical release (the "hot zone") in order to extract casualties and provide field decontamination adjacent to the site of release: Level A [
         <a href="#rid51">
          51
         </a>
         ]. (See
         <a class="local">
          'Field incident response'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          First receivers (hospital decontamination zone)
         </strong>
         – For receivers performing care in the hospital decontamination zone at facilities that meet best practices for emergency planning: Level C, which consists of the following PPE [
         <a href="#rid52">
          52
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Powered air-purifying respirator (PAPR) with protection factor of 1000, and fitted with a combination 99.97 percent high-efficiency particulate air (HEPA)/organic vapor/ acid respirator cartridges (both of these items should be approved by the National Institute of Occupational Safety and Health [NIOSH] or similar agency)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Double layer protective gloves
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chemical resistant suit with openings taped
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Head covering and eye and face protection (if not already part of the PAPR)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Chemical-protective boots
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          First receivers (hospital post-decontamination zone)
         </strong>
         – For receivers performing care in the hospital post-decontamination zone at facilities that meet best practices for emergency planning: normal work clothes and PPE as needed for infection control (eg, gowns, gloves, and/or surgical mask) [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Once the chemical agent is identified and proper monitoring of hazard levels is in place, additional guidelines may apply. First responders and medical providers should receive communication as defined in their regional emergency management plan from appropriate personnel in the regional incident command center to ensure ongoing compliance with PPE standards during the event.
        </p>
        <p class="headingAnchor" id="H12470110">
         <span class="h2">
          Triage
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a mass-casualty incident involving chemical agents, casualties will need to be triaged, or sorted, for medical treatment, decontamination, and transport to medical care or evacuation from the site of release.
        </p>
        <p>
         The paramount question in triage is, "Who can afford to wait?" Most triage categories were developed for trauma patients; however, the general categories of immediate, delayed, minimal, and, in austere conditions, expectant can be adapted to chemical casualties [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
         General triage approaches vary by jurisdiction and include START (simple triage and rapid treatment), SALT (Sort, Assess, Lifesaving Interventions Treatment/Transport), and SMART tag systems. However, these algorithms have primarily been developed for triage of traumatic injuries and focus on medical sorting. Of these, only SALT has suggestions for antidote administration in the event of a chemical exposure.
        </p>
        <p class="headingAnchor" id="H2166300">
         <span class="h3">
          Special considerations for chemical events
         </span>
         <span class="headingEndMark">
          —
         </span>
         Triage systems specific to chemical, biological, radiologic, nuclear, and explosive terrorist events have been developed [
         <a href="#rid54">
          54-57
         </a>
         ]. Although beyond the scope of this topic, training in field triage for chemical terrorism is available through the Chemical Casualty Care Division, United States Army Medical Research Institute of Chemical Defense. (See
         <a class="local">
          'Additional resources'
         </a>
         below.)
        </p>
        <p>
         Field triage guidance for chemical casualties and the triage algorithms, Simple Triage and Rapid Treatment (START and JumpSTART) and Sort – Assess – Life Saving Interventions (SALT) are also discussed
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fchemm.hhs.gov%2Ftriage.htm&amp;token=dp%2BhZUZL0R27seNHDAv8lGD46Sguvkt8B1wx5f39OfSWOPJDxA9TaLgkJwbjICFr&amp;TOPIC_ID=2020" target="_blank">
          here
         </a>
         .
        </p>
        <p>
         Proper field triage of patients exposed to chemical weapons has the following differences from traditional mass casualty field triage:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Time demands are greater.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Personal protective equipment is needed and makes verbal communication and tactile examination challenging. (See
         <a class="local">
          'Protection of providers'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Proper assessment of the type and seriousness of the exposure is more difficult.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sorting needs to occur for decontamination and evacuation in addition to medical treatment.
        </p>
        <p>
        </p>
        <p>
         Special aspects of triage of victims of chemical weapons exposure also include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Trauma is frequently not present.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessment for chemical toxidromes and prompt administration of properly dosed antidotes optimizes outcomes. (See
         <a class="local">
          'Clinical syndromes'
         </a>
         above and
         <a class="local">
          'Antidotes'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Respiratory failure is a serious threat with many exposures and frequently needs to be addressed in the prehospital setting.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For quick onset chemicals (eg, nerve agents or cyanide), latent periods before symptoms can be very short (seconds to minutes). Thus lives may be saved or lost in the prehospital setting.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For other chemicals (eg, phosgene or sulfur mustard), latent periods may be very long and exposure may not be recognized.
        </p>
        <p>
        </p>
        <p>
         Special considerations for triage designation of victims of chemical exposure include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immediate
         </strong>
         – Immediate casualties are those who cannot afford to wait more than a couple of minutes and
         <strong>
          are
         </strong>
         likely to survive with local decontamination, initial medical stabilization, and antidote administration given available resources.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The agents most likely to result in immediate casualties are cyanide and nerve agents; fast-acting antidotes are available for these agents. (See
         <a class="local">
          'Antidotes'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Impending airway compromise or respiratory distress also requires triage as immediate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition, any person with suspicious liquid on the skin must also be considered immediate until prompt (local, spot) decontamination has occurred and the patient is reassessed. (See
         <a class="local">
          'Local or spot decontamination'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Delayed
         </strong>
         – Delayed casualties can wait up to several hours for medical care although if they need rapid local decontamination and prompt field decontamination, they are immediate until local decontamination has been occurred. These patients can obey commands, are not in respiratory distress, have peripheral pulses and no major hemorrhage
         <strong>
          but
         </strong>
         do have injuries that are more than minor. Typically, these patients cannot walk without assistance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In addition to these criteria, patients with exposure to peripherally acting pulmonary agents, vesicants, BZ, and crowd-control agents are typically classified as delayed with respect to medical treatment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Minimal
         </strong>
         – Patients who meet all criteria for delayed care AND have only minor injuries are considered minimal once appropriately decontaminated. These patients are typically able to walk and talk.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For example, patients who have been exposed to nerve agent vapor but then removed from exposure and whose symptoms are now resolving are considered minimal.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Expectant/dead
         </strong>
         – Expectant patients are those who are
         <strong>
          not
         </strong>
         likely to survive given available resources. At the scene of a mass casualty chemical exposure, patients who are not breathing after control of major hemorrhage, opening of the airway, chest decompression, administration of autoinjector antidotes, and, in children, provision of two rescue breaths are classified as dead. Furthermore, patients who have experienced a respiratory or cardiac arrest or continued seizures despite antidote therapy warrant withholding of medical resources if minimal or scant resources are available and there are large numbers of casualties requiring care and transport [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Additional considerations for triage of patients with chemical agent exposure include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Casualties whose only exposure is to vapor assume a lower priority for thorough patient decontamination than those exposed to liquid.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When the chemical agent has a long latent period, the sorting of patients for evacuation may be different than for medical treatment. As an example, a patient who develops shortness of breath after only four hours of exposure to phosgene may be delayed for medical stabilization but urgent for transport to a pulmonary intensive care unit.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Respiratory symptoms occurring less than four hours after exposure to a peripherally acting pulmonary agent or to a vesicant imply a high dose and a guarded prognosis. Although these patients would typically be triaged as delayed, the onset of symptoms so soon after exposure indicates a high dose capable of causing death.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Following a chemical incident, the ratio of casualties presenting with fears of exposure but without objective evidence of toxicity to casualties with objective evidence of poisoning may be as high as 4 to 1, and considerations must be taken to distinguish between these two groups and ensure timely care of the poisoned patients [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H707831">
         <span class="h2">
          Stabilization
         </span>
         <span class="headingEndMark">
          —
         </span>
         Medical assessment and life-saving treatment after a chemical weapons exposure frequently must occur during or prior to field or hospital decontamination to ensure patient survival. During this phase of care, key actions include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          A: Airway
         </strong>
         – Maintain an open airway and, if the patient has traumatic injuries, perform cervical spine stabilization.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          B: Breathing
         </strong>
         – Give oxygen for respiratory distress and, if needed, support breathing with bag-mask ventilation followed by endotracheal intubation. Avoid
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         when performing rapid sequence intubation in patients exposed to nerve gas. (See
         <a class="medical medical_review" href="/z/d/html/339.html" rel="external">
          "Organophosphate and carbamate poisoning", section on 'Initial resuscitation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          C: Circulation
         </strong>
         – Establish intravenous access, obtain initial laboratory studies, and give intravenous antidotes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          D: Immediate decontamination
         </strong>
         – Stop exposure to the chemical agent; actions include application of a gas mask in the field if assisted breathing is not needed, local or spot decontamination of any suspicious liquid on the skin or in wounds, and removing the patient from the source of exposure. (See
         <a class="local">
          'Local or spot decontamination'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          D: Drugs
         </strong>
         – Administer antidotes, including autoinjector administration of antidotes in the field prior to establishment of intravenous access; for chemical warfare agents, specific antidotes are only available against cyanide compounds, nerve agents, and BZ. (See
         <a class="local">
          'Antidotes'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          E: Exposure
         </strong>
         – Remove clothing and perform definitive decontamination while avoiding hypothermia, especially in infants, children, and older adults.
        </p>
        <p>
        </p>
        <p>
         These steps need not occur in a strictly chronological order (eg, effective ventilation of an apneic nerve-agent casualty may be impossible before administration of sufficient
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         to break nerve-agent-induced bronchospasm) but should be accomplished nearly simultaneously if possible.
        </p>
        <p>
         Even in the absence of specific antidotes in the field, general stabilization measures as described may, in many cases, permit casualty survival until definitive treatment can be begun. However, maximum survival following exposures to cyanide and nerve agents requires that antidotes be available to appropriately trained first responders in the field as critical life -saving measures during triage of casualties (
         <a class="graphic graphic_algorithm graphicRef90283" href="/z/d/graphic/90283.html" rel="external">
          algorithm 2
         </a>
         ) [
         <a href="#rid60">
          60-62
         </a>
         ]. (See
         <a class="local">
          'Triage'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H4870439">
         <span class="h2">
          Decontamination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Proper decontamination consists of local or spot decontamination of any liquids on the skin, removal of clothing, and copious irrigation of the skin with lukewarm water and, if available, mild soap. Although mass decontamination may be accomplished in the field, decontamination should also occur at receiving hospitals.
        </p>
        <p>
         This section provides a basic approach to decontamination. However, proper decontamination requires specialized equipment, extensive training of personnel, and close collaboration between hospitals and regional incident command. Proper setup and performance of decontamination are discussed in detail elsewhere [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5890503">
         <span class="h3">
          Local or spot decontamination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Local or spot immediate decontamination of skin should be performed during triage and stabilization (
         <a class="graphic graphic_algorithm graphicRef90283" href="/z/d/graphic/90283.html" rel="external">
          algorithm 2
         </a>
         ). (See
         <a class="local">
          'Stabilization'
         </a>
         above.)
        </p>
        <p>
         The following agents may be used for spot decontamination [
         <a href="#rid3">
          3,63,64
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reactive Skin Decontamination Lotion (RSDL)
         </strong>
         – RSDL is specifically formulated to neutralize the toxicity of the liquid nerve agent VX and blister agents such as sulfur mustard and Lewisite. It acts within seconds of being applied to the skin and is the preferred spot decontamination method for victims of a chemical attack [
         <a href="#rid63">
          63,65
         </a>
         ]. The lotion is packaged on a foam applicator inside a single use pouch. The lotion is applied within three minutes of contamination and rubbed gently on the skin for two minutes, and the nontoxic residue is washed away at a later time (
         <a class="graphic graphic_picture graphicRef90991" href="/z/d/graphic/90991.html" rel="external">
          picture 1
         </a>
         ). Although reasonable to perform, application of RSDL to wounds is considered off label use. Application of RSDL to the eyes is not recommended.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other topical absorbents
         </strong>
         – If RSDL is not available, porous material such as activated charcoal, Fuller's earth, clay, tissue paper, flour, or bread, although less effective, may be applied to areas of contaminated skin to adsorb agent followed by irrigation. If an adsorbent is not available, irrigation alone should be performed.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Irrigation
         </strong>
         – If RSDL is not available, any available adsorbent material (towels, tissue paper, charcoal, bread, clay-rich soil, etc) should be applied, allowed to remain on the skin for 30 seconds to two minutes, and removed by wiping, flushing with water, or (preferably) gentle but thorough washing with soap and water. A dilute bleach solution (0.5 percent hypochlorite, made by mixing one part standard household bleach with nine parts water) may also be used followed by rinsing with plain water. The use of straight bleach (5 percent hypochlorite or greater) is to be discouraged because of potential damage to the skin that may cause increased absorption of the chemical agent. For oily agents, such as sulfur mustard and VX, water plus a mild soap may be more effective than water alone.
        </p>
        <p>
        </p>
        <p>
         Because many chemical agents start damaging or penetrating skin within a couple of minutes of exposure, the importance of immediate decontamination cannot be overemphasized. However, delayed decontamination, even if too late to prevent skin effects such as blistering from vesicants, may prevent continued absorption of the substance and the accumulation of a lethal internal dose [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5890664">
         <span class="h3">
          Field decontamination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mass decontamination is an important aspect of field incident response and often consists of stations for disrobing followed by showering or assisted decontamination. However, in civilian settings, patients might bypass field decontamination stations and report directly to medical facilities for care. Thus, receiving facilities should still perform definitive decontamination of all exposed patients prior to bringing them into clean areas to avoid contamination. (See
         <a class="local">
          'Field incident response'
         </a>
         above.)
        </p>
        <p>
         The proper setup and performance of field decontamination are discussed in detail elsewhere [
         <a href="#rid63">
          63
         </a>
         ]. Training is available to qualified providers in the United States under the auspices of the Chemical Casualty Care Division of the United States Army Medical Research Institute of Chemical Defense (USAMRICD), Army Chemical Defense. (See
         <a class="local">
          'Additional resources'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H5890670">
         <span class="h3">
          Hospital decontamination
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chemical decontamination consists of removal of all clothing and thorough washing of the skin and hair with lukewarm water and soap
         <strong>
          before
         </strong>
         the patient is brought into the clean area of the emergency department or other parts of the hospital.
        </p>
        <p>
         Important considerations include [
         <a href="#rid63">
          63
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Persons performing chemical decontamination at first receiving facilities should wear Level C personal protective equipment (PPE). (See
         <a class="local">
          'Protection of providers'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Providers assisting with decontamination should ensure that cleansing of the skin does not cause open wounds.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Water temperature should be controlled so that hypothermia is avoided, especially in infants, children, and older adults.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Once chemical decontamination has occurred, the patient should be dried, dressed in clean hospital gowns, and escorted or transported into the clean zone of the emergency department.
        </p>
        <p>
        </p>
        <p>
         During chemical decontamination, medical stabilization and treatment may be necessary, particularly for victims exposed to cyanide or nerve agents. Thus, decontamination areas should have supplies and medications necessary to provide initial stabilization while decontamination is performed and medical personnel are outfitted in Level C PPE.
        </p>
        <p>
         Contaminated patients should
         <strong>
          not
         </strong>
         be brought into clean areas of receiving facilities (hospitals and emergency departments) because they can sicken staff and contaminate the facility, thereby reducing the capacity of the health care system to respond to the chemical incident [
         <a href="#rid67">
          67
         </a>
         ]. Such patients should be kept outside and undergo decontamination before being brought into the hospital. A security perimeter and lock down of the receiving facility are key actions to prevent inadvertent contamination by such patients.
        </p>
        <p>
         However, some patients may require emergency medical stabilization before thorough decontamination (see
         <a class="local">
          'Stabilization'
         </a>
         above). A complete plan responds to this need by mandating the establishment of an emergency medical treatment station in the "dirty" area after triage but before thorough decontamination.
        </p>
        <p>
         Each hospital should have a management plan that maximizes the efficiency and efficacy of decontamination. Proposed concept of operations for health care facilities is discussed in detail elsewhere [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
         Important aspects of such planning include [
         <a href="#rid68">
          68
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Establishment of a designated fixed or rapidly deployed decontamination facility
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Proper training of staff in the donning and removal of Level C PPE
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Triage plan for contaminated patients that separates them into medical and nonmedical decontamination
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decontamination procedures that maintain privacy and avoid hypothermia
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Secondary triage after decontamination
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assurance of adequate personnel and supplies to perform simultaneous medical stabilization and chemical decontamination
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6336088">
         <span class="h2">
          Initial management of specific exposures
         </span>
         <span class="headingEndMark">
          —
         </span>
         The table provides the mechanism of action, clinical findings, recommended decontamination, and management for chemical weapons exposures (
         <a class="graphic graphic_table graphicRef90716" href="/z/d/graphic/90716.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H11645282">
         <span class="h3">
          Antidotes
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antidotes are available for chemical exposure to nerve agents, cyanide compounds, and BZ. Dosing below is based upon recommendations provided by the United States Department of Health and Human Services [
         <a href="#rid69">
          69
         </a>
         ]. Based upon animal studies, all nerve agent antidotes appear to have bioavailability after intraosseous (IO) administration that is equivalent to intravenous (IV) administration [
         <a href="#rid70">
          70
         </a>
         ]. Thus, the IO route is an option for nerve agent antidote administration, although in a mass casualty situation, IM administration permits more rapid treatment of a greater number of casualties.
        </p>
        <p class="headingAnchor" id="H21809693">
         <span class="h4">
          Nerve agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Various autoinjectors are available for the rapid intramuscular (IM) administration of nerve agent antidotes including the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mark I kit
         </strong>
         (no longer manufactured) – One
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         2 mg and one
         <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">
          pralidoxime
         </a>
         600 mg autoinjector. Atropine should always be given first.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duodote
         </strong>
         – One autoinjector that administers
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         2 mg with
         <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">
          pralidoxime
         </a>
         600 mg simultaneously.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antidote Treatment-Nerve Agent, Autoinjector (ATNAA)
         </strong>
         – One autoinjector that administers
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         2.1 mg and
         <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">
          pralidoxime
         </a>
         600 mg simultaneously.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Convulsive Antidote, Nerve Agent (CANA)
         </strong>
         – One autoinjector containing
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         10 mg.
        </p>
        <p>
        </p>
        <p>
         In addition, studies of a
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         autoinjector to treat children and adults with seizures caused by nerve agents have been funded by the United States Department of Health and Human Services [
         <a href="#rid71">
          71
         </a>
         ]. Midazolam is more rapidly absorbed after intramuscular administration than is
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         .
        </p>
        <p>
         Medical personnel should be familiar with the contents and operation of the autoinjector that they will use. Many jurisdictions have stockpiles of nerve agent autoinjectors available for rapid deployment in the event of a nerve agent release. Availability of such stockpiles is essential to an effective response because just one patient with moderate or severe effects of nerve agent exposure can rapidly deplete typical hospital stocks of
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         and
         <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">
          pralidoxime
         </a>
         .
        </p>
        <p>
         The correct use of autoinjectors is described
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fchemm.hhs.gov%2Fantidote_nerveagents.htm&amp;token=dp%2BhZUZL0R27seNHDAv8lLuLWpp1hwMa6M%2BDwUiB%2FQzsiWEaOpPLR9zGDrZjkk6sGRGqueJOJ8PrfQaS59dqkA%3D%3D&amp;TOPIC_ID=2020" target="_blank">
          here
         </a>
         .
        </p>
        <p>
         Treat adults, including pregnant women, with
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">
          pralidoxime
         </a>
         , and benzodiazepines based upon clinical effects as follows [
         <a href="#rid72">
          72
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mild effects
         </strong>
         – Only selected adults with mild clinical effects warrant treatment as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Miosis alone with no respiratory symptoms – No antidote.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Miosis and severe rhinorrhea –
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          Atropine
         </a>
         0.05 mg/kg IV, IM, IO (adult maximum 2 mg per dose or one atropine autoinjector containing 2 mg atropine).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Do
         <strong>
          not
         </strong>
         give
         <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">
          pralidoxime
         </a>
         or benzodiazepines.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Moderate effects
         </strong>
         – For adults with mild effects
         <strong>
          plus
         </strong>
         moderate respiratory distress, nausea and vomiting, weakness, and/or muscle fasciculations give the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          Atropine
         </a>
         0.05 mg/kg IV, IM, IO (adult maximum 4 mg per dose or two atropine 2 mg autoinjectors); double the initial dose and repeat every two to five minutes as needed to control bronchial secretions or bronchospasm and permit ventilation.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">
          Pralidoxime
         </a>
         25 mg/kg IV, IO, or IM (adult maximum single dose 1 g IV; 2 g IM or two pralidoxime 600 mg autoinjectors) with or after
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         , may repeat within 30 to 60 minutes as needed up to a total dose of 45 mg/kg, then again every 12 hours for up to two doses as needed for persistent weakness or high atropine requirement; continuous infusion may be needed to control severe muscarinic symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">
          Pralidoxime
         </a>
         is initially reconstituted to 50 mg/mL (1 g in 20 mL sterile water) for IV or IO administration, and the total dose infused over 30 minutes, or it may be given by continuous infusion (loading dose 25 mg/kg over 30 minutes, then 10 mg/kg per hour).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Do
         <strong>
          not
         </strong>
         give benzodiazepines.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe effects
         </strong>
         – For adults with moderate effects
         <strong>
          plus
         </strong>
         coma, seizures, apnea, or paralysis (or for anyone with (a) significant respiratory distress or (b) systemic effects), give the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          Atropine
         </a>
         0.1 mg/kg IM only (adult maximum 6 mg per dose or three atropine 2 mg autoinjectors).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9915" href="/z/d/drug information/9915.html" rel="external">
          Scopolamine
         </a>
         adult dose: 1 mg IM, IV, or via inhalation as a single dose with the initial dose of
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Pediatric dosing (based upon preoperative parenteral dosing):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Children 6 months to 3 years: 0.15 mg IM, IV, or via inhalation as a single dose with the initial dose of
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         .
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Children over 3 to 6 years: 0.3 mg IM, IV, or via inhalation as a single dose with the initial dose of
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         .
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Children over 6 years of age to puberty: 0.6 mg IM, IV, or via inhalation as a single dose with the initial dose of
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="9915" href="/z/d/drug information/9915.html" rel="external">
          Scopolamine
         </a>
         is a tropane alkaloid that penetrates the CNS at lower doses than
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         . Based upon animal models, when given early enough, it can prevent nerve-agent-associated seizures and may be synergistic with atropine for the treatment of muscarinic symptoms [
         <a href="#rid73">
          73-75
         </a>
         ]. It does
         <strong>
          not
         </strong>
         replace atropine (which is still useful in treating muscarinic effects outside the CNS), but even a small dose of scopolamine can significantly reduce the total dose of atropine needed to treat a nerve-agent casualty and permit conservation of atropine during a large chemical event.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Although optimal dosing of
         <a class="drug drug_general" data-topicid="9915" href="/z/d/drug information/9915.html" rel="external">
          scopolamine
         </a>
         after nerve agent exposure in humans is unknown, the suggested single adult dose of 1 mg is chosen to conserve
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         while avoiding delirium. This dose is conservative given that, in healthy unexposed adults, delirium may occur at parenteral scopolamine doses of ≥1.5 mg.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="9915" href="/z/d/drug information/9915.html" rel="external">
          Scopolamine
         </a>
         is currently not widely available in the United States and is not approved by the US Food and Drug Administration (FDA) for nerve agent exposure, although when available it could be given off label where a physician-patient relationship exists.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">
          Pralidoxime
         </a>
         45 mg/kg IV, IO, or IM (adult maximum single dose 2 g IV and 2 g IM or three pralidoxime 600 mg autoinjectors) with or after
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         . May repeat after 60 minutes as needed up to 2 g IV, then again every 12 hours for up to two doses as needed for persistent weakness or high atropine requirement; continuous infusion may be needed to control severe muscarinic symptoms.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Benzodiazepines, options include:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          Diazepam
         </a>
         0.3 mg/kg (maximum 10 mg) IV, IO OR
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         : 0.1 mg/kg IV, IO, IM (maximum 4 mg) OR
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         : 0.2 mg/kg (maximum 10 mg) IM OR two to three diazepam 10 mg (convulsive antidote, nerve agent [CANA]) autoinjectors.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing in infants and children
         </strong>
         – When possible, weight-based dosing should be given to children up to the adult maximum doses described above and according to clinical effects.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For children with severe, life-threatening nerve agent toxicity who lack intravenous access, and for whom more precise mg/kg IM dosing would be logistically impossible, suggested autoinjector dosing guidelines for
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">
          pralidoxime
         </a>
         , and valium by weight are as follows [
         <a href="#rid69">
          69
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          ≤25 kg
         </strong>
         – One
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         2 mg and
         <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">
          pralidoxime
         </a>
         600 mg autoinjector; IM valium 5 mg (do not use autoinjector)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          26 to 50 kg
         </strong>
         – Two
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         2 mg and two 600 mg
         <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">
          pralidoxime
         </a>
         autoinjectors and one valium 10 mg autoinjector
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          ≥50 kg
         </strong>
         – Three
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         2 mg, three
         <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">
          pralidoxime
         </a>
         600 mg, and two to three valium 10 mg autoinjectors
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing in older adults
         </strong>
         – Dosing should be adjusted in frail older patients as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mild effects
         </strong>
         –
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          Atropine
         </a>
         (maximum dose 1 mg or one atropine 1 mg autoinjector)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Moderate effects
         </strong>
         –
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          Atropine
         </a>
         as for mild effects;
         <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">
          pralidoxime
         </a>
         10 mg/kg IM or one pralidoxime 600 mg autoinjector
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Severe effects
         </strong>
         –
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          Atropine
         </a>
         2 to 4 mg (one or two atropine 2 mg autoinjectors);
         <a class="drug drug_general" data-topicid="9802" href="/z/d/drug information/9802.html" rel="external">
          Pralidoxime
         </a>
         25 mg/kg (two to three pralidoxime 600 mg autoinjectors; and valium 5 to 10 mg every 15 minutes (total maximum dose 25 mg) or two valium 10 mg autoinjectors
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of liquid exposure to Novichok
         </strong>
         – Individuals with skin exposure to liquid Novichok can be very difficult to treat once they become symptomatic [
         <a href="#rid27">
          27,31
         </a>
         ], but the long latent periods (up to two days) following this kind of exposure present a unique opportunity for presymptomatic management. Those who may have been exposed in this manner need to be identified, sequestered, and decontaminated by showering and with reactive skin decontamination lotion (RSDL). Cholinesterase monitoring should begin, and the Chemical Casualty Care Division of the United States Army Medical Research Institute of Chemical Defense (USAMRICD) should be contacted. Specialized consultative advice can be found at
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fusamricd.health.mil%2Ftraining%2Fccd%2FPages%2Fdefault.aspx&amp;token=RgyOEg2lxKXVQFHZB7Z9JOIk7vjcqaGolNfpwkKfbVCTVi7B%2FwOkZlr1VCXYz2pBJCHxkFx23la7ad4ouFg58q8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=2020" target="_blank">
          USAMRICD
         </a>
         . (See
         <a class="local">
          'Additional resources'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21809883">
         <span class="h4">
          Cyanide
         </span>
         <span class="headingEndMark">
          —
         </span>
         Availability of treatment varies by region and hospital. Immediately below is a series of antidotal management recommendations, based upon treatment availability, for patients with
         <strong>
          probable
         </strong>
         cyanide exposure (see
         <a class="medical medical_review" href="/z/d/html/299.html" rel="external">
          "Cyanide poisoning", section on 'Suspected cyanide intoxication'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients where
         <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">
          hydroxocobalamin
         </a>
         is available, it is administered as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">
          Hydroxocobalamin
         </a>
         70 mg/kg IV over 15 minutes (15 mL/minute) (5 g is the standard and maximum adult dose). The Cyanokit contains 2.5 g (one reconstituted vial). In patients &lt;40 kg, the initial dose may be repeated once, but total dose should not exceed 5 g (two vials).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients without contraindication to nitrites (eg, carbon monoxide toxicity), and where
         <a class="drug drug_general" data-topicid="8813" href="/z/d/drug information/8813.html" rel="external">
          hydroxocobalamin
         </a>
         is not available, use combinations of
         <a class="drug drug_general" data-topicid="8767" href="/z/d/drug information/8767.html" rel="external">
          amyl nitrite
         </a>
         and
         <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">
          sodium nitrite
         </a>
         to induce methemoglobinemia, and
         <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">
          sodium thiosulfate
         </a>
         to act as a sulfur donor as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8767" href="/z/d/drug information/8767.html" rel="external">
          Amyl nitrite
         </a>
         inhaled by the patient (held under the patient's nose or via the endotracheal tube) for 30 seconds of each minute, for three minutes
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="85782" href="/z/d/drug information/85782.html" rel="external">
          Sodium nitrite
         </a>
         10 mg/kg IV
         <strong>
          AND
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9939" href="/z/d/drug information/9939.html" rel="external">
          Sodium thiosulfate
         </a>
         (25 percent) 1.65 mL/kg IV (maximum dose 12.5 g)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Where 4-dimethylaminophenol (4-DMAP) or dicobalt edetate is available, they are options
         <strong>
          only
         </strong>
         when other antidotes are
         <strong>
          not
         </strong>
         available, but should only be given after consultation with local critical care, military and/or toxicology experts. They are only for parenteral, not intramuscular, administration.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3905629">
         <span class="h4">
          BZ (3-quinuclidinyl benzilate)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with anticholinergic toxicity do well with supportive care alone, but some may benefit from antidotal therapy with
         <a class="drug drug_general" data-topicid="9770" href="/z/d/drug information/9770.html" rel="external">
          physostigmine
         </a>
         . One approach is as follows (see
         <a class="medical medical_review" href="/z/d/html/305.html" rel="external">
          "Anticholinergic poisoning", section on 'Antidotal therapy with physostigmine for severe toxicity'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Consider treating mild to moderate agitation with benzodiazepines alone (eg,
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         ), although
         <a class="drug drug_general" data-topicid="9770" href="/z/d/drug information/9770.html" rel="external">
          physostigmine
         </a>
         is more effective for this purpose than are benzodiazepines;
         <strong>
          do not
         </strong>
         use phenothiazines or butyrophenones (eg,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who manifest
         <strong>
          both peripheral
         </strong>
         (eg, dilated pupils, dry mouth, and/or flushing)
         <strong>
          AND moderate central
         </strong>
         (moderate to severe agitation/delirium or seizures) anticholinergic toxicity
         <strong>
          without contraindications
         </strong>
         to
         <a class="drug drug_general" data-topicid="9770" href="/z/d/drug information/9770.html" rel="external">
          physostigmine
         </a>
         (eg, widened QRS on electrocardiogram) should receive the following dose: 0.5 to 2 mg (0.02 mg/kg IV, up to a maximum of 0.5 mg per dose in pediatric patients); physostigmine should be given by slow IV infusion, generally over five minutes. Benzodiazepines (eg,
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         ) may also be administered as needed for seizures.
        </p>
        <p>
        </p>
        <p>
         Because
         <a class="drug drug_general" data-topicid="9770" href="/z/d/drug information/9770.html" rel="external">
          physostigmine
         </a>
         is uncommonly used and unfamiliar to many clinicians, it is best given after consultation with a medical toxicologist or regional poison center, if possible. In the United States, call 1-800-222-1222 to be connected to the nearest poison control center. Contact information for poison centers around the world is provided separately. (See
         <a class="local">
          'Additional resources'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3338859306">
         <span class="h3">
          Crowd-control agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients who have been exposed to crowd-control agents such as OC (oleoresin capsicum, pepper spray), CS (o-chlorobenzylidene malononitrile), and CN (mace) have mild effects and do well with removal from exposure and supportive care as needed. However, serious ocular and respiratory effects can occur [
         <a href="#rid76">
          76-79
         </a>
         ]. Skin blisters from irritant or allergic contact dermatitis can result in 12 hours to a week after exposure if decontamination is delayed or incomplete [
         <a href="#rid80">
          80
         </a>
         ]. Allergic contact dermatitis and tracheobronchitis may also occur with repeated exposure to CS [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
         Risk factors for serious injury include exposure in an enclosed space, underlying pulmonary disease (eg, asthma or chronic obstructive pulmonary disease), and delivery by projectile mechanisms. Since these compounds are solids, and since one method of dispersion is their forceful ejection from canisters, ocular effects can include impaction of particles in the cornea. High doses (high concentrations and high durations of exposure) in confined spaces can lead to pulmonary edema and fatal acute lung injury.
        </p>
        <p>
         There is no antidote for these agents. Treatment begins with removal from exposure. Contact lenses should be removed before eye irrigation. The clinician should perform copious irrigation of eyes and skin with water or normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         . Inform the patient that transient worsening of pain with water or saline is normal. Hypochlorite (bleach) solutions, which can cause additional skin damage and, in the case of CS (o-chlorobenzylidene malononitrile), can generate toxic epoxides, are contraindicated.
        </p>
        <p>
         Symptomatic management is as follows (
         <a class="graphic graphic_table graphicRef90716" href="/z/d/graphic/90716.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid76">
          76,82
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Respiratory distress – If respiratory symptoms do not resolve with removal from exposure and fresh air, patients should receive supplemental oxygen (humidified, if available). Further care is determined by the presence of upper or lower airway findings:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Upper airway (stridor, drooling, hoarseness, or laryngospasm):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Inhaled racemic
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         for stridor or upper airway obstruction
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Pulmonary toilet (frequent suctioning)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Bronchoscopy for severe upper airway obstruction
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lower airway (wheezing):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Inhaled short-acting beta-2 agonists (eg,
         <a class="drug drug_general" data-topicid="9396" href="/z/d/drug information/9396.html" rel="external">
          albuterol
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Systemic corticosteroids (eg, oral
         <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">
          prednisolone
         </a>
         or
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         , or intravenous prednisolone)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eye exposure – Patients with significant eye pain, tearing, and blepharospasm warrant the following treatment:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         If no signs of penetrating or serious blunt eye injury, provide topical ophthalmic anesthetic (eg,
         <a class="drug drug_general" data-topicid="9824" href="/z/d/drug information/9824.html" rel="external">
          proparacaine
         </a>
         0.5 percent, one drop to each eye)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Perform irrigation for at least 20 minutes with fresh water or normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         (see
         <a class="medical medical_review" href="/z/d/html/345.html" rel="external">
          "Topical chemical burns: Initial evaluation and management"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Perform a complete ocular examination, including
         <a class="drug drug_general" data-topicid="8461" href="/z/d/drug information/8461.html" rel="external">
          fluorescein
         </a>
         staining to identify corneal abrasions or other injuries to the eye (see
         <a class="medical medical_review" href="/z/d/html/13903.html" rel="external">
          "Approach to diagnosis and initial treatment of eye injuries in the emergency department"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H42">
         <span class="h1">
          ADDITIONAL RESOURCES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following resources provide a means of rapid notification of a chemical weapons attack within the United States and access to specific medical guidance and consultation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Emergency Federal Hotline
         </strong>
         (United States) – Federal chemical and biological hotline (US Government Response Center): 1-800-424-8802
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chemical Hazards Emergency Medical Management (CHEMM)
         </strong>
         – An interactive online and downloadable clinical
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fchemm.hhs.gov%2Findex.html&amp;token=dp%2BhZUZL0R27seNHDAv8lPVrZTr5LmKIlDf%2BMKp07YJDsB2m6uMYTDPsrM5KaFiz&amp;TOPIC_ID=2020" target="_blank">
          guide
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Centers for Disease Control and Prevention
         </strong>
         – The physician's telephone line is (404) 639-3311. The CDC also provides a
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Femergency.cdc.gov%2Fhazards-specific.asp&amp;token=%2FXpciKoGXD%2FNBcI56myByDRjoT4dcMcT2ii0wl7fRfWd4DE6fEkN5HedQYeRy8gqG9LQtkNzCbABLBlR3Kxv0g%3D%3D&amp;TOPIC_ID=2020" target="_blank">
          website
         </a>
         that addresses all hazards preparedness and medical care, including both bioterrorism and chemical terrorism.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Army Chemical Defense
         </strong>
         – The United States Army Medical Research Institute of Chemical Defense (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fusamricd.health.mil%2Ftraining%2Fccd%2FPages%2Fdefault.aspx&amp;token=RgyOEg2lxKXVQFHZB7Z9JOIk7vjcqaGolNfpwkKfbVCTVi7B%2FwOkZlr1VCXYz2pBJCHxkFx23la7ad4ouFg58q8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=2020" target="_blank">
          USAMRICD
         </a>
         ), at Aberdeen Proving Ground, Maryland is an important source of current research and clinical data and consultation concerning the medical response to chemical-warfare agents.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The Chemical Casualty Care Division (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fusamricd.health.mil%2Ftraining%2Fccd%2FPages%2Fdefault.aspx&amp;token=RgyOEg2lxKXVQFHZB7Z9JOIk7vjcqaGolNfpwkKfbVCTVi7B%2FwOkZlr1VCXYz2pBJCHxkFx23la7ad4ouFg58q8AtSQsFLDSFqHlsS1NKKs%3D&amp;TOPIC_ID=2020" target="_blank">
          CCCD
         </a>
         ; 1-833-238-7756) is the USAMRICD division responsible for training, education, and clinical consultation. The CCCD provides comprehensive courses, a variety of training materials, and consultative services.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The United States Army also has developed clinical practice guidelines for
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fjts.health.mil%2Fassets%2Fdocs%2Fcpgs%2FChemical_Biological%2C_Radiological_Nuclear_Injury_Part1_Initial_Response_01_May_2018_ID69.pdf&amp;token=2aA4K0PEFVlZWjGrPah68hrvRzxxJNrFvLuuT0WNGRf1OVomzvVvd5%2BpTu6P0MLspMIF0r1E%2Fsz%2FDP%2ByzpYkCVAKG2mh4kJ3iTQBw86N%2FkEnARJl0DOOdPiQUoc5mNYu3WRnvGzl06kulDmQf1aOPLR5OikunIt%2FVxqNIq6RWc4%3D&amp;TOPIC_ID=2020" target="_blank">
          initial response
         </a>
         and
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fjts.health.mil%2Fassets%2Fdocs%2Fcpgs%2FChemical_Biological_Radiological_Nuclear_Injury_Response_Part_2_Medical_Management_25_Mar_2022_ID69.pdf&amp;token=VkVDo086ISLX8niWW%2B8jvLXfuKrqmijLX0XBAAhIN%2FyntPVFMIwfu9l4ZIY3VoH7elB%2BcGVHye6Y1%2BGyxW6fXRdHh00Lj4y%2F4IDJ1RLia6ptqzrCBMZFUqYd66PEkk5FzC8TbUVGun5I9xedCaWYesWQRJEZlLt9nxz2Jkz7CH4%3D&amp;TOPIC_ID=2020" target="_blank">
          medical management
         </a>
         of chemical, biological, and radiological nuclear injury.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          US Food and Drug Administration (FDA)
         </strong>
         – The FDA has an excellent counterterrorism
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.fda.gov%2Femergency-preparedness-and-response&amp;token=j9iGCEymK%2BAgWt1Mk1AOOlwx3%2FVOqrhkhmiiNzqRGupeE4wU6k09Ft2e253URIRB0c%2BfGHe5T4%2B87R365t4qpA%3D%3D&amp;TOPIC_ID=2020" target="_blank">
          website
         </a>
         that provides up-to-date information on antidotes for chemical agents, including pediatric dosing as it is validated. The main telephone number for the drug center at the FDA is (301) 594-5400, in Rockville Maryland. The Chemical and Bioterrorism Office at the FDA is located in CDER (Center for Drug Evaluation and Research). The telephone number for the FDA counterterrorism office is (301) 827-7777.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chemical biological incident response force
         </strong>
         – Following the 1995 Tokyo subway attack, the United States Marine Corps formed the Chemical Biological Incident Response Force (CBIRF) based near Washington, DC [
         <a href="#rid83">
          83
         </a>
         ]. The CBIRF will deploy anywhere in the United States and provide capabilities for agent detection and identification, casualty search and rescue, personnel decontamination, and emergency care and stabilization of contaminated personnel. They can decontaminate 200 casualties per hour, and they have been trained and equipped to identify 120,000 toxic industrial chemicals. The CBIRF can be requested by local, state, or federal agencies. Contact information is available
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.cbirf.marines.mil%2F&amp;token=R4Uiw8%2FbmPVaqNHRDqpXLGFuxVneIShSUFZNMWmplx%2B6bX%2B1jaoXegDny0bP%2BeC9&amp;TOPIC_ID=2020" target="_blank">
          here
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          American Academy of Pediatrics (AAP)
         </strong>
         – Pediatric considerations during a chemical terrorism event and for preparedness are discussed in reports from the AAP [
         <a href="#rid84">
          84,85
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2147468274">
         <span class="h2">
          Regional poison control centers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">
          "Society guideline links: Regional poison control centers"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H749551278">
         <span class="h2">
          Society guideline links
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/135135.html" rel="external">
          "Society guideline links: Chemical terrorism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6247929">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chemical agent definitions
         </strong>
         – Chemical compounds capable of creating mass casualties include (see
         <a class="local">
          'Chemical agent definitions'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Traditional chemical agents (pulmonary agents, "blood" agents [cyanide compounds], vesicants [blister agents], nerve agents, and the anticholinergic agent BZ)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Nontraditional agents
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Toxic industrial chemicals (TICs)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Crowd-control agents
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Mid-spectrum agents (biological toxins) (see
         <a class="medical medical_review" href="/z/d/html/2735.html" rel="external">
          "Identifying and managing casualties of biological terrorism", section on 'Toxins of concern'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Recognition of chemical exposure
         </strong>
         – Recognition of a chemical weapons release is based upon the following (see
         <a class="local">
          'Recognition of chemical exposure'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Incident features that suggest a chemical exposure (
         <a class="graphic graphic_table graphicRef90149" href="/z/d/graphic/90149.html" rel="external">
          table 2
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Clinical syndromes among casualties (
         <a class="graphic graphic_algorithm graphicRef90159" href="/z/d/graphic/90159.html" rel="external">
          algorithm 1
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Confirmation using rapid detection methods and clinical laboratory studies
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Field incident response and decontamination
         </strong>
         – Key medical actions in the field include protection of first responders (Level A personal protection equipment [PPE] as defined by OSHA [
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.osha.gov%2Flaws-regs%2Fregulations%2Fstandardnumber%2F1910%2F1910.120AppB&amp;token=cBdz3Q1CH7IVGsHQmyQigtfn%2BaDVRU0eDZjMBw5O6b7cs7yLDsrQCaoVNpj%2BFigGHpksD08Fp6NLAj2J2Z9%2BnSFc1D7lxZk8Knu31Gn6Vc0%3D&amp;TOPIC_ID=2020" target="_blank">
          https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.120AppB
         </a>
         .]) patient triage, spot decontamination, administration of antidotes to victims of suspected cyanide or nerve gas exposure (
         <a class="graphic graphic_algorithm graphicRef90283" href="/z/d/graphic/90283.html" rel="external">
          algorithm 2
         </a>
         ), and field decontamination. (See
         <a class="local">
          'Field incident response'
         </a>
         above and
         <a class="local">
          'Local or spot decontamination'
         </a>
         above and
         <a class="local">
          'Field decontamination'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hospital incident response
         </strong>
         – Upon identification or notification of a chemical weapons release, receiving facilities should secure all entrances and hospital grounds, establish a security perimeter, and set up a decontamination zone that is outside the clean parts of the facility. Disaster plans should be activated. Facility incident command and close communication with local emergency management authorities should be established. (See
         <a class="local">
          'Hospital incident response'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial management
         </strong>
         – Initial hospital management of patients with chemical weapons exposure warrants the following actions:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Protection of first receivers prior to decontamination (Level C PPE as defined by OSHA [
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.osha.gov%2Flaws-regs%2Fregulations%2Fstandardnumber%2F1910%2F1910.120AppB&amp;token=cBdz3Q1CH7IVGsHQmyQigtfn%2BaDVRU0eDZjMBw5O6b7cs7yLDsrQCaoVNpj%2BFigGHpksD08Fp6NLAj2J2Z9%2BnSFc1D7lxZk8Knu31Gn6Vc0%3D&amp;TOPIC_ID=2020" target="_blank">
          https://www.osha.gov/laws-regs/regulations/standardnumber/1910/1910.120AppB
         </a>
         ]) (see
         <a class="local">
          'Protection of providers'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Triage with immediate stabilization of airway, breathing, and circulation and, for victims of cyanide or nerve agent exposure, antidote administration (see
         <a class="local">
          'Triage'
         </a>
         above and
         <a class="local">
          'Stabilization'
         </a>
         above and
         <a class="local">
          'Antidotes'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Spot decontamination (see
         <a class="local">
          'Local or spot decontamination'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Definitive decontamination based upon the specific exposure (
         <a class="graphic graphic_table graphicRef90716" href="/z/d/graphic/90716.html" rel="external">
          table 1
         </a>
         ) (see
         <a class="local">
          'Hospital decontamination'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Agent-specific medical care and administration of antidotes (
         <a class="graphic graphic_table graphicRef90716" href="/z/d/graphic/90716.html" rel="external">
          table 1
         </a>
         ) (see
         <a class="local">
          'Initial management of specific exposures'
         </a>
         above and
         <a class="local">
          'Antidotes'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Additional resources
         </strong>
         – Several online resources provide additional information on the response to a chemical weapons release including access to specific medical guidance and consultation. (See
         <a class="local">
          'Additional resources'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21979050">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The views expressed in this topic are those of the author(s) and do not reflect the official policy of the Department of Army, Department of Defense, or the US Government.
        </p>
        <p>
         The author and editors acknowledge John Beary, III, MD, and Arkadi Chines, MD, both of whom contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Born CT, Briggs SM, Ciraulo DL, et al. Disasters and mass casualties: II. explosive, biologic, chemical, and nuclear agents. J Am Acad Orthop Surg 2007; 15:461.
          </a>
         </li>
         <li class="breakAll">
          Couch D. United States Armed Forces Nuclear, Biological and Chemical Survival Manual, Basic Books, New York 2003.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henretig FM, Cieslak TJ, Eitzen EM Jr. Biological and chemical terrorism. J Pediatr 2002; 141:311.
          </a>
         </li>
         <li class="breakAll">
          Acquista A. The Survival Guide: what to do in a biological, chemical or nuclear emergency, Random House, New York 2003.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greenfield RA, Brown BR, Hutchins JB, et al. Microbiological, biological, and chemical weapons of warfare and terrorism. Am J Med Sci 2002; 323:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furlow B. Biological, chemical and radiological terrorism. Radiol Technol 2003; 75:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heymann WR. Threats of biological and chemical warfare on civilian populations. J Am Acad Dermatol 2004; 51:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gosden C, Gardener D. Weapons of mass destruction--threats and responses. BMJ 2005; 331:397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fry DE. Chemical threats. Surg Clin North Am 2006; 86:637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prockop LD. Weapons of mass destruction: Overview of the CBRNEs (Chemical, Biological, Radiological, Nuclear, and Explosives). J Neurol Sci 2006; 249:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bland SA. Chemical, biological and radiation casualties: critical care considerations. J R Army Med Corps 2009; 155:160.
          </a>
         </li>
         <li class="breakAll">
          Convention on the Prohibition of the Development, Production, Stockpiling and Use of Chemical Weapons and on their Destruction (Chemical Weapons Convention). http://www.opcw.org/chemical-weapons-convention/ (Accessed on May 21, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kadivar H, Adams SC. Treatment of chemical and biological warfare injuries: insights derived from the 1984 Iraqi attack on Majnoon Island. Mil Med 1991; 156:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hu H, Cook-Deegan R, Shukri A. The use of chemical weapons. Conducting an investigation using survey epidemiology. JAMA 1989; 262:640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okumura T, Suzuki K, Fukuda A, et al. The Tokyo subway sarin attack: disaster management, Part 1: Community emergency response. Acad Emerg Med 1998; 5:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okumura T, Suzuki K, Fukuda A, et al. The Tokyo subway sarin attack: disaster management, Part 2: Hospital response. Acad Emerg Med 1998; 5:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakagawa T, Tu AT. Murders with VX: Aum Shinrikyo in Japan and the assassination of Kim Jong-Nam in Malaysia. Forensic Toxicology 2018; :542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones R, Wills B, Kang C. Chlorine gas: an evolving hazardous material threat and unconventional weapon. West J Emerg Med 2010; 11:151.
          </a>
         </li>
         <li class="breakAll">
          Rubin A. Chlorine gas attack by truck bomber kills up to 30 in Iraq. New York Times, April 7, 2007. http://www.nytimes.com/2007/04/07/world/africa/07iht-web-0407-iraq.5182467.html (Accessed on May 04, 2016).
         </li>
         <li class="breakAll">
          Shaheen K. Assad regime accused of 35 chlorine attacks since mid-march. The Guardian, May 24, 2015. http://www.theguardian.com/world/2015/may/24/syria-regime-accused-of-using-chlorine-bombs-on-civilians. (Accessed on May 04, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vogel L. WHO releases guidelines for treating chemical warfare victims after possible Syria attacks. CMAJ 2013; 185:E665.
          </a>
         </li>
         <li class="breakAll">
          Report on Allegations of the Use of Chemical Weapons in the Ghouta Area of Damascus on 21 August 2013. United Nations Mission to Investigate Allegations of the Use of Chemical Weapons in the Syrian Arab Republic. United Nations. http://www.un.org/disarmament/content/slideshow/Secretary_General_Report_of_CW_Investigation.pdf. (Accessed on October 01, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zarocostas . Syria chemical attacks: preparing for the unconscionable. Lancet 2017.
          </a>
         </li>
         <li class="breakAll">
          Sellström A, Cairns S, Barbeschi M. United Nations mission to investigate allegations of the use of chemical weapons in the Syrian Arab Republic. Final Report. 2013 Dec 12;12.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alsaleh OI, Elsafti Elsaeidy AM, Saeed S, et al. Acute Health Effects and Outcome Following Sarin Gas Attacks in Khan Shaykhun, Syria. Cureus 2022; 14:e22188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vale JA, Marrs TC OBE, Maynard RL CBE. Novichok: a murderous nerve agent attack in the UK. Clin Toxicol (Phila) 2018; 56:1093.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steindl D, Boehmerle W, Körner R, et al. Novichok nerve agent poisoning. Lancet 2021; 397:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chai PR, Berlyand Y, Goralnick E, et al. Wartime toxicology: the spectre of chemical and radiological warfare in Ukraine. Toxicol Commun 2022; 6:52.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson PD. Emergency management of chemical weapons injuries. J Pharm Pract 2012; 25:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuca K, Pohanka M. Chemical warfare agents. EXS 2010; 100:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chai PR, Hayes BD, Erickson TB, Boyer EW. Novichok agents: a historical, current, and toxicological perspective. Toxicol Commun 2018; 2:45.
          </a>
         </li>
         <li class="breakAll">
          Swaran JSF, Flora G, Saxena G. Arsenicals: Toxicity, their use as chemical warfare agents, and possible remedial measures. In: Handbook of Toxicology of Chemical Warfare Agents, Gupta RC (Ed), Academic Press, 2009. p.109.
         </li>
         <li class="breakAll">
          Homeland Security Presidential Directive/HSPD-18. http://www.fas.org/irp/offdocs/nspd/hspd-18.html (Accessed on May 10, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burklow TR, Yu CE, Madsen JM. Industrial chemicals: terrorist weapons of opportunity. Pediatr Ann 2003; 32:230.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reedy SJ, Schwartz MD, Morgan BW. Suicide fads: frequency and characteristics of hydrogen sulfide suicides in the United States. West J Emerg Med 2011; 12:300.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Madsen JM. Toxins as weapons of mass destruction. A comparison and contrast with biological-warfare and chemical-warfare agents. Clin Lab Med 2001; 21:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aas P. The threat of mid-spectrum chemical warfare agents. Prehosp Disaster Med 2003; 18:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wormser U. Toxicology of mustard gas. Trends Pharmacol Sci 1991; 12:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel MM, Schier JG, Belson MG. Recognition of illness associated with covert chemical releases. Pediatr Emerg Care 2006; 22:592.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cieslak TJ, Rowe JR, Kortepeter MG, et al. A field-expedient algorithmic approach to the clinical management of chemical and biological casualties. Mil Med 2000; 165:659.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ciottone GR. Toxidrome Recognition in Chemical-Weapons Attacks. N Engl J Med 2018; 378:1611.
          </a>
         </li>
         <li class="breakAll">
          Tuorinsky SD, Sciuto AM. Toxic inhalational injury and toxic industrial chemicals. In: Medical aspects of chemical warfare, 2nd ed, Tuorinsky SD (Ed), Office of the Surgeon General,TMM Publications, Washington, DC 2008. p.339.
         </li>
         <li class="breakAll">
          Hurst CG, Petrali JP, Barillo DJ, et al. Vesicants. In: Medical aspects of chemical warfare, 2nd ed, Tuorinsky SD (Ed), Office of the Surgeon General,TMM Publications, Washington, DC 2008. p.259.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Busl KM, Bleck TP. Treatment of neuroterrorism. Neurotherapeutics 2012; 9:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guidotti TL. Hydrogen sulfide: advances in understanding human toxicity. Int J Toxicol 2010; 29:569.
          </a>
         </li>
         <li class="breakAll">
          Rimpel LY, Boehm DE, O'Hern MR, et al. Chemical defense equipment. In: Medical Aspects of Chemical Warfare, 2nd ed, Tuorinsky SD (Ed), United States Department of the Army, Office of the Surgeon General at TMM Publications, Bordent Institute, Washington, DC 2008. p.559.
         </li>
         <li class="breakAll">
          Capacio BR, Smith JR, Gordon RK, et al. Medical diagnostics. In: Medical Aspects of Chemical Warfare, 2nd ed, Tuorinsky SD (Ed), Unites States, Department of the Army, Office of the Surgeon General, Borden Instittute, Washington, DC 2008. p.691.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fidder A, Noort D, Hulst AG, et al. Biomonitoring of exposure to lewisite based on adducts to haemoglobin. Arch Toxicol 2000; 74:207.
          </a>
         </li>
         <li class="breakAll">
          On-site Activities. Chemical Hazards Emergency Medical Management. US Department of Health and Human Services. https://chemm.hhs.gov/onsite.htm (Accessed on January 03, 2022).
         </li>
         <li class="breakAll">
          General description and discussion of the levels of protection and protective gear. Occupational Safety and Health Standards: Hazardous Materials. Standard number: 1910.120 App B. www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=STANDARDS&amp;p_id=9767 (Accessed on August 07, 2013).
         </li>
         <li class="breakAll">
          Occupational Safety and Health Administration (OSHA). Best Practices for Protecting EMS Responders during Treatment and Transport of Victims of Hazardous Substance Releases. http://www.osha.gov/Publications/OSHA3370-protecting-EMS-respondersSM.pdf (Accessed on May 10, 2013).
         </li>
         <li class="breakAll">
          Occupational Safety and Health Administration (OSHA). OSHA Best Practices for Hospital-based First Receivers of Victims from Mass Casualty Incidents Involving the Release of Hazardous Substances. http://www.osha.gov/dts/osta/bestpractices/html/hospital_first receivers.html and http://www.osha.gov/dits/osta/bestpractices/firstreceivers_hospital.pdf (Accessed on May 10, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLaughlin S. Chemical reaction. A look at OSHA's guidance for chemical incident first receivers. Health Facil Manage 2005; 18:36, 38, 40.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cone DC, Koenig KL. Mass casualty triage in the chemical, biological, radiological, or nuclear environment. Eur J Emerg Med 2005; 12:287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Subbarao I, Johnson C, Bond WF, et al. Symptom-based, algorithmic approach for handling the initial encounter with victims of a potential terrorist attack. Prehosp Disaster Med 2005; 20:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramesh AC, Kumar S. Triage, monitoring, and treatment of mass casualty events involving chemical, biological, radiological, or nuclear agents. J Pharm Bioallied Sci 2010; 2:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Culley JM, Svendsen E. A review of the literature on the validity of mass casualty triage systems with a focus on chemical exposures. Am J Disaster Med 2014; 9:137.
          </a>
         </li>
         <li class="breakAll">
          Triage guidelines. Chemical Hazards Medical Management. US Department of Health and Human Services. http://www.chemm.nlm.nih.gov/triage.htm#sec1 (Accessed on August 07, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown JS Jr. Psychiatric issues in toxic exposures. Psychiatr Clin North Am 2007; 30:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawrence DT, Kirk MA. Chemical terrorism attacks: update on antidotes. Emerg Med Clin North Am 2007; 25:567.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pettineo C, Aitchison R, Leikin SM, et al. Biological and chemical weapons of mass destruction: updated clinical therapeutic countermeasures since 2003. Am J Ther 2009; 16:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rodgers GC Jr, Condurache CT. Antidotes and treatments for chemical warfare/terrorism agents: an evidence-based review. Clin Pharmacol Ther 2010; 88:318.
          </a>
         </li>
         <li class="breakAll">
          Braue EH, Boardman CH, Hurst CG. Decontamination of chemical casualties. In: Medical Aspects of Chemical Warfare, 2nd ed, Tuorinsky SD (Ed), United States Department of the Army, Office of the Surgeon General at TMM Publications, Borden Institute, Washington, DC, 2008, p. 527. https://ke.army.mil/bordeninstitute/published_volumes/chemwarfare/Chem-ch16_pg527-558.pdf (Accessed on August 27, 2013).
         </li>
         <li class="breakAll">
          Protopam® Injection Supplement S-024 DRAFT Package Insert. Food and Drug Administration, United States of America. http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/14134s24lbl.pdf (Accessed on September 20, 2010).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schwartz MD, Hurst CG, Kirk MA, et al. Reactive skin decontamination lotion (RSDL) for the decontamination of chemical warfare agent (CWA) dermal exposure. Curr Pharm Biotechnol 2012; 13:1971.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Houston M, Hendrickson RG. Decontamination. Crit Care Clin 2005; 21:653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byers M, Russell M, Lockey DJ. Clinical care in the "Hot Zone". Emerg Med J 2008; 25:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macintyre AG, Christopher GW, Eitzen E Jr, et al. Weapons of mass destruction events with contaminated casualties: effective planning for health care facilities. JAMA 2000; 283:242.
          </a>
         </li>
         <li class="breakAll">
          Nerve agents - prehospital management. Chemical Hazards Emergency Medical Management. US Department of Health and Human Services. http://www.chemm.nlm.nih.gov/na_prehospital_mmg.htm#top (Accessed on September 07, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray DB, Eddleston M, Thomas S, et al. Rapid and complete bioavailability of antidotes for organophosphorus nerve agent and cyanide poisoning in minipigs after intraosseous administration. Ann Emerg Med 2012; 60:424.
          </a>
         </li>
         <li class="breakAll">
          HHS pursues nerve agent anti-seizure drug for children and adults. US Department of Health and Human Services. HHS.gov. http://www.hhs.gov/news/press/2013pres/09/20130925b.html (Accessed on October 07, 2013).
         </li>
         <li class="breakAll">
          Nerve Agent Treatment- Autoinjector Instructions. Chemical Hazards Emergency Medical Management. US Department of Health and Human Services. https://chemm.hhs.gov/antidote_nerveagents.htm (Accessed on January 03, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shih TM, Rowland TC, McDonough JH. Anticonvulsants for nerve agent-induced seizures: The influence of the therapeutic dose of atropine. J Pharmacol Exp Ther 2007; 320:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koplovitz I, Schulz S. Perspectives on the use of scopolamine as an adjunct treatment to enhance survival following organophosphorus nerve agent poisoning. Mil Med 2010; 175:878.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perkins MW, Pierre Z, Rezk P, et al. Protective effects of aerosolized scopolamine against soman-induced acute respiratory toxicity in guinea pigs. Int J Toxicol 2011; 30:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schep LJ, Slaughter RJ, McBride DI. Riot control agents: the tear gases CN, CS and OC-a medical review. J R Army Med Corps 2015; 161:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karaman E, Erturan S, Duman C, et al. Acute laryngeal and bronchial obstruction after CS (o-chlorobenzylidenemalononitrile) gas inhalation. Eur Arch Otorhinolaryngol 2009; 266:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haar RJ, Iacopino V, Ranadive N, et al. Health impacts of chemical irritants used for crowd control: a systematic review of the injuries and deaths caused by tear gas and pepper spray. BMC Public Health 2017; 17:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kearney T, Hiatt P, Birdsall E, Smollin C. Pepper spray injury severity: ten-year case experience of a poison control system. Prehosp Emerg Care 2014; 18:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dimitroglou Y, Rachiotis G, Hadjichristodoulou C. Exposure to the riot control agent CS and potential health effects: a systematic review of the evidence. Int J Environ Res Public Health 2015; 12:1397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lam RPK, Wong KW, Wan CK. Allergic contact dermatitis and tracheobronchitis associated with repeated exposure to tear gas. Lancet 2020; 396:e12.
          </a>
         </li>
         <li class="breakAll">
          Poison Center issues recommendations on treating crowd control agents. School of Medicine news. Wayne State University. https://today.wayne.edu/medicine/news/2020/06/07/poison-center-issues-recommendations-on-treating-crowd-control-agents-37518 (Accessed on June 23, 2020).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gourley, SR. US Marine Corps Chemical Biological Incident Response Force. Military Medical Technology 2003; 7:6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chung S, Baum CR, Nyquist AC, DISASTER PREPAREDNESS ADVISORY COUNCIL, COUNCIL ON ENVIRONMENTAL HEALTH, COMMITTEE ON INFECTIOUS DISEASES. Chemical-Biological Terrorism and Its Impact on Children. Pediatrics 2020; 145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DISASTER PREPAREDNESS ADVISORY COUNCIL. Medical Countermeasures for Children in Public Health Emergencies, Disasters, or Terrorism. Pediatrics 2016; 137:e20154273.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2020 Version 59.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17664366" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Disasters and mass casualties: II. explosive, biologic, chemical, and nuclear agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17664366" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Disasters and mass casualties: II. explosive, biologic, chemical, and nuclear agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12219050" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Biological and chemical terrorism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12219050" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Biological and chemical terrorism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12074487" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Microbiological, biological, and chemical weapons of warfare and terrorism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14671828" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Biological, chemical and radiological terrorism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15337990" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Threats of biological and chemical warfare on civilian populations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16096310" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Weapons of mass destruction--threats and responses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16781273" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Chemical threats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16920155" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Weapons of mass destruction: Overview of the CBRNEs (Chemical, Biological, Radiological, Nuclear, and Explosives).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20095187" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Chemical, biological and radiation casualties: critical care considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20095187" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Chemical, biological and radiation casualties: critical care considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2030837" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Treatment of chemical and biological warfare injuries: insights derived from the 1984 Iraqi attack on Majnoon Island.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2746816" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The use of chemical weapons. Conducting an investigation using survey epidemiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9660289" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : The Tokyo subway sarin attack: disaster management, Part 1: Community emergency response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9660290" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The Tokyo subway sarin attack: disaster management, Part 2: Hospital response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Murders with VX: Aum Shinrikyo in Japan and the assassination of Kim Jong-Nam in Malaysia
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20823965" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Chlorine gas: an evolving hazardous material threat and unconventional weapon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20823965" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Chlorine gas: an evolving hazardous material threat and unconventional weapon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20823965" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Chlorine gas: an evolving hazardous material threat and unconventional weapon.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24003104" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : WHO releases guidelines for treating chemical warfare victims after possible Syria attacks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24003104" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : WHO releases guidelines for treating chemical warfare victims after possible Syria attacks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Syria chemical attacks: preparing for the unconscionable
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Syria chemical attacks: preparing for the unconscionable
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35308713" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Acute Health Effects and Outcome Following Sarin Gas Attacks in Khan Shaykhun, Syria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29757015" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Novichok: a murderous nerve agent attack in the UK.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33357496" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Novichok nerve agent poisoning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35497376" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Wartime toxicology: the spectre of chemical and radiological warfare in Ukraine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22080590" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Emergency management of chemical weapons injuries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20358695" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Chemical warfare agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30003185" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Novichok agents: a historical, current, and toxicological perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30003185" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Novichok agents: a historical, current, and toxicological perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30003185" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Novichok agents: a historical, current, and toxicological perspective.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12723117" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Industrial chemicals: terrorist weapons of opportunity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21731786" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Suicide fads: frequency and characteristics of hydrogen sulfide suicides in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11577702" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Toxins as weapons of mass destruction. A comparison and contrast with biological-warfare and chemical-warfare agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15310042" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The threat of mid-spectrum chemical warfare agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2063482" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Toxicology of mustard gas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16912631" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Recognition of illness associated with covert chemical releases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11011535" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : A field-expedient algorithmic approach to the clinical management of chemical and biological casualties.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29694809" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Toxidrome Recognition in Chemical-Weapons Attacks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29694809" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Toxidrome Recognition in Chemical-Weapons Attacks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29694809" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Toxidrome Recognition in Chemical-Weapons Attacks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22227729" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Treatment of neuroterrorism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21076123" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Hydrogen sulfide: advances in understanding human toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21076123" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Hydrogen sulfide: advances in understanding human toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21076123" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Hydrogen sulfide: advances in understanding human toxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10959794" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Biomonitoring of exposure to lewisite based on adducts to haemoglobin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10959794" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Biomonitoring of exposure to lewisite based on adducts to haemoglobin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10959794" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Biomonitoring of exposure to lewisite based on adducts to haemoglobin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10959794" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Biomonitoring of exposure to lewisite based on adducts to haemoglobin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10959794" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Biomonitoring of exposure to lewisite based on adducts to haemoglobin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15898455" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Chemical reaction. A look at OSHA's guidance for chemical incident first receivers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16276260" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Mass casualty triage in the chemical, biological, radiological, or nuclear environment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16295166" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Symptom-based, algorithmic approach for handling the initial encounter with victims of a potential terrorist attack.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21829319" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Triage, monitoring, and treatment of mass casualty events involving chemical, biological, radiological, or nuclear agents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25068943" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : A review of the literature on the validity of mass casualty triage systems with a focus on chemical exposures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25068943" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : A review of the literature on the validity of mass casualty triage systems with a focus on chemical exposures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17938048" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Psychiatric issues in toxic exposures.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17482033" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Chemical terrorism attacks: update on antidotes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22573054" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Biological and chemical weapons of mass destruction: updated clinical therapeutic countermeasures since 2003.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20686476" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Antidotes and treatments for chemical warfare/terrorism agents: an evidence-based review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20686476" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Antidotes and treatments for chemical warfare/terrorism agents: an evidence-based review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20686476" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Antidotes and treatments for chemical warfare/terrorism agents: an evidence-based review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22352732" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Reactive skin decontamination lotion (RSDL) for the decontamination of chemical warfare agent (CWA) dermal exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16168307" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Decontamination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18212153" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Clinical care in the "Hot Zone".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10634341" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Weapons of mass destruction events with contaminated casualties: effective planning for health care facilities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10634341" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Weapons of mass destruction events with contaminated casualties: effective planning for health care facilities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22738685" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Rapid and complete bioavailability of antidotes for organophosphorus nerve agent and cyanide poisoning in minipigs after intraosseous administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22738685" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Rapid and complete bioavailability of antidotes for organophosphorus nerve agent and cyanide poisoning in minipigs after intraosseous administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22738685" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Rapid and complete bioavailability of antidotes for organophosphorus nerve agent and cyanide poisoning in minipigs after intraosseous administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17015638" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Anticonvulsants for nerve agent-induced seizures: The influence of the therapeutic dose of atropine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21121499" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Perspectives on the use of scopolamine as an adjunct treatment to enhance survival following organophosphorus nerve agent poisoning.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21960666" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Protective effects of aerosolized scopolamine against soman-induced acute respiratory toxicity in guinea pigs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24379300" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Riot control agents: the tear gases CN, CS and OC-a medical review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18365225" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Acute laryngeal and bronchial obstruction after CS (o-chlorobenzylidenemalononitrile) gas inhalation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29052530" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Health impacts of chemical irritants used for crowd control: a systematic review of the injuries and deaths caused by tear gas and pepper spray.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24669935" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Pepper spray injury severity: ten-year case experience of a poison control system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25633030" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Exposure to the riot control agent CS and potential health effects: a systematic review of the evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32673597" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Allergic contact dermatitis and tracheobronchitis associated with repeated exposure to tear gas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32673597" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Allergic contact dermatitis and tracheobronchitis associated with repeated exposure to tear gas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : US Marine Corps Chemical Biological Incident Response Force
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31988168" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Chemical-Biological Terrorism and Its Impact on Children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26729737" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Medical Countermeasures for Children in Public Health Emergencies, Disasters, or Terrorism.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
